SHANGHAI, June 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, presented two latest clinical study results of its independently developed Nectin-4-targeting ADC 9MW2821 (Bulumtatug Fuvedotin, BFv) in cervical cancer at the European Society for Medical Oncology Gynaecological Cancers Congress 2026 (ESMO Gynae 2026) in Copenhagen, Denmark, held June 17–19, 2026. The two studies demonstrated that 9MW2821 has a manageable safety profile and promising therapeutic effects in patients with cervical cancer, with particularly notable survival benefits observed in immunotherapy-pretreated patients. The combination of 9MW2821 with a PD-1 inhibitor showed encouraging antitumor activity in advanced cervical cancer.
Oral Presentation: BFv in Recurrent or Metastatic Cervical Cancer
The Phase I/II cervical cancer cohort of this clinical study (NCT05216965) enrolled patients with recurrent or metastatic cervical cancer (r/m CC) who had progressed on or after platinum-based chemotherapy with or without bevacizumab and received no more than 2 previous systemic regimens for recurrent or metastatic disease. Subjects received 1.25 mg/kg of BFv by intravenous infusion on days 1, 8, and 15 each 28-day cycle.
As of March 20, 2025, 55 patients were enrolled. Of these, 49.09% patients had received prior platinum-based doublet chemotherapy plus bevacizumab, and 58.18% had received prior platinum-based doublet chemotherapy plus immune checkpoint inhibitors.
Among the 53 patients evaluable for efficacy, the confirmed objective response rate (cORR) and disease control rate (DCR) were 32.08% and 81.13%, respectively, with 1 complete response (1.87%) and 17 partial responses (30.19%). Median progression-free survival (mPFS) was 3.9 months and median duration of response (mDOR) was 5.98 months. Median overall survival (mOS) was 19.4 months, with a 12-month OS rate of 72.7% and a 24-month OS rate of 49.1%.
Among the 31 post-IO patients evaluable for efficacy, cORR and DCR were 29.00% and 77.40%, respectively. Median PFS was 4.0 months and median DoR was 9.1 months. Median OS has not yet been reached. The 12-month OS rate was 76.6% and the 24-month OS rate was 51.1%. No new safety signals were observed in this follow-up.
Poster Presentation: BFv in Combination with Toripalimab for Recurrent or Metastatic Cervical Cancer
The study consists of a phase lb safety run-in followed by a phase lI cohort expansion, enrolling patients with cervical cancer who had received ≥ 1 line therapy (Phase lb), and who had no prior systemic chemotherapy (Phase ll). Patients received BFv 1.25mg/kg on days 1, 8 and Toripalimab at 240mg on day 1 of each 21-days cycle. The primary endpoints were safety and preliminary efficacy.
As of March 19, 2026, a total of 19 patients were enrolled, including 3 previously treated patients and 16 treatment-naïve patients. The mean patient age was 57.8 years, and 89.5% had squamous cell carcinoma. 13 patients were evaluable for efficacy with at least one post-baseline tumor assessment. The ORR was 76.9% (10/13), including 1 complete response (CR) and 9 partial responses (PR), and the DCR was 100%. In treatment-naïve patients, the ORR reached 80.0% (8/10). Treatment-related adverse events (TRAEs) were primarily Grade 1–2, and no new safety signals were observed.
The preliminary findings demonstrate a synergistic effect of the Nectin-4-targeting ADC combined with a PD-1 inhibitor in the treatment of cervical cancer, and also offer the potential to establish a new first-line therapy for patients with recurrent or metastatic cervical cancer.
About 9MW2821 (BFv)
9MW2821 is a novel Nectin-4-targeting ADC independently developed by Mabwell based on its ADC development platform. It is the world's first Nectin-4 ADC to enter Phase III clinical trials for cervical cancer (CC) and triple-negative breast cancer (TNBC). Four pivotal Phase III clinical studies are underway. 9MW2821 has obtained FDA Fast Track Designation for three indications, Orphan Drug Designation for one indication, and Breakthrough Therapy Designation from the CDE of NMPA for two indications.
Interim analysis for the Phase III clinical trials of urothelial carcinoma (UC) monotherapy, UC combination therapy and CC monotherapy are planned to be conducted in 2026, and Applications for pre-NDA meetings are expected to be submitted to the Center for Drug Evaluation under the National Medical Products Administration based on the data of interim analysis.
About Mabwell
Mabwell (688062.SH, 02493.HK) is an innovation-driven biopharmaceutical company with capabilities spanning the entire pharmaceutical value chain. The company is committed to providing more effective and accessible therapies to meet global medical needs, with a focus on oncology and aging-related diseases. Mabwell's mission is "Explore Life, Benefit Health" and its vision is "Innovation, from Ideas to Reality." For more information, please visit www.mabwell.com/en.
Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company's product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. "Forward-looking statements" are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would," and similar expressions and the negatives of those terms.
Forward-looking statements are based on the Company's current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company's control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results.
The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress
